James M Ford

List of Publications by Year
in descending order

200 papers	14,796 citations	16411 64 h-index	19690 117 g-index
208 all docs	208 docs citations	208 times ranked	18329 citing authors

#	Article	IF	Citations
1	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 3764-3773.	3.2	733
2	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 2015, 33, 3660-3667.	0.8	603
3	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germlineCDH1mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	1.5	479
4	Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment. Journal of Clinical Oncology, 2014, 32, 2001-2009.	0.8	442
5	p53-Mediated DNA Repair Responses to UV Radiation: Studies of Mouse Cells Lacking p53 , p21 , and/or gadd45 Genes. Molecular and Cellular Biology, 2000, 20, 3705-3714.	1.1	411
6	Clinical Interpretation and Implications of Whole-Genome Sequencing. JAMA - Journal of the American Medical Association, 2014, 311, 1035.	3.8	398
7	Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 2360.	3.8	394
8	Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer, 2009, 115, 665-672.	2.0	353
9	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	13.5	334
10	Expression of Wild-type p53 Is Required for Efficient Global Genomic Nucleotide Excision Repair in UV-irradiated Human Fibroblasts. Journal of Biological Chemistry, 1997, 272, 28073-28080.	1.6	318
11	Xeroderma Pigmentosum p48 Gene Enhances Global Genomic Repair and Suppresses UV-Induced Mutagenesis. Molecular Cell, 2000, 5, 737-744.	4.5	312
12	Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2005, 63, 320-323.	0.4	308
13	Gemcitabine Chemotherapy and Single-Fraction Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 678-686.	0.4	308
14	Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer. Annals of Internal Medicine, 2011, 155, 69.	2.0	303
15	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncology, 2015, 1, 943.	3.4	294
16	p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12985-12990.	3.3	280
17	Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncology, The, 2020, 21, e386-e397.	5.1	237
18	Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas. Cancer Research, 2010, 70, 512-519.	0.4	236

#	Article	IF	Citations
19	Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 181-188.	0.4	230
20	In Vivo Recruitment of XPC to UV-induced Cyclobutane Pyrimidine Dimers by the DDB2 Gene Product. Journal of Biological Chemistry, 2003, 278, 46906-46910.	1.6	225
21	BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nature Genetics, 2002, 32, 180-184.	9.4	218
22	American Society of Clinical Oncology Expert Statement: Collection and Use of a Cancer Family History for Oncology Providers. Journal of Clinical Oncology, 2014, 32, 833-840.	0.8	210
23	HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19482-19487.	3.3	207
24	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutationâ€“Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. Journal of Clinical Oncology, 2015, 33, 1895-1901.	0.8	200
25	Long-read genome sequencing identifies causal structural variation in a Mendelian disease. Genetics in Medicine, 2018, 20, 159-163.	1.1	189
26	Characterization of a Recurrent Germ Line Mutation of the E-Cadherin Gene: Implications for Genetic Testing and Clinical Management. Clinical Cancer Research, 2005, 11, 5401-5409.	3.2	187
27	Colorectal Cancer Screening. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 8-61.	2.3	185
28	Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS ONE, 2013, 8, e54014.	1.1	174
29	A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. Journal of Molecular Diagnostics, 2015, 17, 533-544.	1.2	167
30	CDH1 Truncating Mutations in the E-Cadherin Gene. Annals of Surgery, 2007, 245, 873-879.	2.1	157
31	p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair, 2003, 2, 947-954.	1.3	150
32	Poly(ADP-Ribose) Polymerase Inhibition: â€œTargetedâ€•Therapy for Triple-Negative Breast Cancer. Clinical Cancer Research, 2010, 16, 4702-4710.	3.2	149
33	Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin. Cancer Research, 2010, 70, 7970-7980.	0.4	147
34	Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Research and Treatment, 2012, 133, 1125-1130.	1.1	144
35	Risk-reducing Total Gastrectomy for Germline Mutations in E-cadherin (CDH1): Pathologic Findings With Clinical Implications. American Journal of Surgical Pathology, 2008, 32, 799-809.	2.1	137
36	Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genetics in Medicine, 2018, 20, 234-239.	1.1	131

#	Article	IF	Citations
37	Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase. Cancer Research, 2009, 69, 3589-3596.	0.4	128
38	18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1420-1425.	0.4	119
39	HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 13-24.	0.6	118
40	NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 939-949.	2.3	116
41	Second Primary Breast Cancer Occurrence According to Hormone Receptor Status. Journal of the National Cancer Institute, 2009, 101, 1058-1065.	3.0	114
42	Functional characterization of global genomic DNA repair and its implications for cancer. Mutation Research - Reviews in Mutation Research, 2003, 544, 107-114.	2.4	110
43	Metastatic tumor evolution and organoid modeling implicate TGFBR2as a cancer driver in diffuse gastric cancer. Genome Biology, 2014, 15, 428.	3.8	110
44	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1465-1475.	2.3	109
45	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer, 2017, 3, 22.	2.3	108
46	Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 577, 195-202.	0.4	100
47	Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. Cancer Discovery, 2015, 5, 488-505.	7.7	97
48	Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase Î· on ATR checkpoint signaling. EMBO Journal, 2006, 25, 2605-2614.	3.5	94
49	Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis. PLoS ONE, 2012, 7, e43994.	1.1	93
50	Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13792-13797.	3.3	93
51	Reversal of Stathmin-Mediated Resistance to Paclitaxel and Vinblastine in Human Breast Carcinoma Cells. Molecular Pharmacology, 2007, 71, 1233-1240.	1.0	92
52	Microsatellite Instability and Mismatch Repair Protein Defects in Ovarian Epithelial Neoplasms in Patients 50 Years of Age and Younger. American Journal of Surgical Pathology, 2008, 32, 1029-1037.	2.1	91
53	Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Research and Treatment, 2018, 168, 625-630.	1.1	87
54	The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. DNA Repair, 2003, 2, 819-826.	1.3	85

#	Article	IF	Citations
55	A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer. Annals of Surgical Oncology, 2011, 18, 2594-2598.	0.7	84
56	Comprehensive spectrum ofBRCA1andBRCA2deleterious mutations in breast cancer in Asian countries. Journal of Medical Genetics, 2016, 53, 15-23.	1.5	82
57	Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 605-613.	1.1	80
58	Colorectal Cancer Screening, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 959-968.	2.3	80
59	A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs. Journal of Oncology Practice, 2017, 13, e108-e119.	2.5	80
60	Hereditary diffuse gastric cancer. Cancer, 2008, 113, 1850-1856.	2.0	77
61	Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer. Nature Genetics, 2022, 54, 985-995.	9.4	77
62	Genetic predisposition to gastric cancer. Seminars in Oncology, 2016, 43, 554-559.	0.8	72
63	p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo. Carcinogenesis, 2003, 24, 843-850.	1.3	68
64	Multigene Panel Testing in Oncology Practice. JAMA Oncology, 2015, 1, 277.	3.4	68
65	The p53-regulated Cyclin-dependent Kinase Inhibitor, p21 (cip1, waf1, sdi1), Is Not Required for Global Genomic and Transcription-coupled Nucleotide Excision Repair of UV-induced DNA Photoproducts. Journal of Biological Chemistry, 2001, 276, 25813-25822.	1.6	66
66	Genetic Testing by Cancer Site. Cancer Journal (Sudbury, Mass), 2012, 18, 355-363.	1.0	65
67	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, 2018, 24, 2851-2858.	3.2	65
68	Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Familial Cancer, 2008, 7, 179-186.	0.9	63
69	Performance ofBRCA1/2Mutation Prediction Models in Asian Americans. Journal of Clinical Oncology, 2008, 26, 4752-4758.	0.8	57
70	Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases. Genome Medicine, 2017, 9, 57.	3.6	56
71	Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. Clinical Cancer Research, 2017, 23, 3365-3370.	3.2	55
72	HAT1 Coordinates Histone Production and Acetylation via H4 Promoter Binding. Molecular Cell, 2019, 75, 711-724.e5.	4.5	55

#	Article	IF	Citations
73	American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome. Gastroenterology, 2015, 149, 783-813.e20.	0.6	51
74	A Kinase-Independent Function of c-Abl in Promoting Proteolytic Destruction of Damaged DNA Binding Proteins. Molecular Cell, 2006, 22, 489-499.	4.5	50
75	Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells. Molecular Carcinogenesis, 2000, 29, 17-24.	1.3	48
76	Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs. Oncotarget, 2018, 9, 12316-12322.	0.8	46
77	Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacology, 2011, 11, 7.	0.4	43
78	The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. Cancer Genetics, 2015, 208, 448-454.	0.2	43
79	Germ Line Mutations of Mismatch Repair Genes in Hereditary Nonpolyposis Colorectal Cancer Patients with Small Bowel Cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study: Table 1.. Clinical Cancer Research, 2006, 12, 3389-3393.	3.2	42
80	BRCA1 and p53: compensatory roles in DNA repair. Journal of Molecular Medicine, 2003, 81, 700-707.	1.7	41
81	Parent decisionâ€making around the genetic testing of children for germline TP53 mutations. Cancer, 2015, 121, 286-293.	2.0	41
82	Molecular Profiling of Gastric Cancer: Toward Personalized Cancer Medicine. Journal of Clinical Oncology, 2013, 31, 838-839.	0.8	38
83	Discovery and functional characterization of a neomorphic PTEN mutation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13976-13981.	3.3	38
84	Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel. Journal of Molecular Diagnostics, 2016, 18, 580-594.	1.2	38
85	Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.. Journal of Clinical Oncology, 2019, 37, 3006-3006.	0.8	38
86	MITI minimum information guidelines for highly multiplexed tissue images. Nature Methods, 2022, 19, 262-267.	9.0	37
87	The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype. European Journal of Human Genetics, 2014, 22, 617-624.	1.4	36
88	Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. Cancer Genetics and Cytogenetics, 2009, 193, 9-18.	1.0	34
89	Patient communication of cancer genetic test results in a diverse population. Translational Behavioral Medicine, 2018, 8, 85-94.	1.2	34
90	Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. Current Opinion in Obstetrics and Gynecology, 2015, 27, 23-33.	0.9	33

#	Article	IF	Citations
91	Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR. Translational Medicine (Sunnyvale, Calif), 2012, 02, .	0.4	33
92	Molecular Inversion Probe Analysis of Gene Copy Alterations Reveals Distinct Categories of Colorectal Carcinoma. Cancer Research, 2006, 66, 7910-7919.	0.4	30
93	PARP inhibitors in breast cancer. Clinical Advances in Hematology and Oncology, 2010, 8, 629-35.	0.3	29
94	PARP Inhibitors for the Treatment and Prevention of Breast Cancer. Current Breast Cancer Reports, 2010, 2, 190-197.	0.5	26
95	Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells. Cancer Letters, 2014, 343, 217-223.	3.2	24
96	Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions. Health Affairs, 2018, 37, 751-756.	2.5	24
97	Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT â€˜basketâ€™ trial.. Journal of Clinical Oncology, 2021, 39, 320-320.	0.8	24
98	Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. JCO Precision Oncology, 2019, 3, 1-12.	1.5	23
99	Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105.. Journal of Clinical Oncology, 2014, 32, 1000-1000.	0.8	23
100	A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer. Familial Cancer, 2011, 10, 233-237.	0.9	21
101	Therapeutic Targeting of BRCA1-Mutated Breast Cancers with Agents That Activate DNA Repair. Cancer Research, 2014, 74, 6205-6215.	0.4	21
102	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research, 2020, 26, 2704-2710.	3.2	21
103	Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. Cancer, 2021, 127, 1275-1285.	2.0	21
104	Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations. BMC Medical Genomics, 2019, 12, 84.	0.7	20
105	The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair. DNA Repair, 2009, 8, 795-802.	1.3	19
106	Accuracy of BRCA1/2ÂMutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort. World Journal of Surgery, 2012, 36, 702-713.	0.8	19
107	A Chimeric ATP-Linked Nucleotide Enables Luminescence Signaling of Damage Surveillance by MTH1, a Cancer Target. Journal of the American Chemical Society, 2016, 138, 9005-9008.	6.6	19
108	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value in Health, 2018, 21, 1062-1068.	0.1	19

#	Article	IF	Citations
109	Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Health Expectations, 2005, 8, 221-233.	1.1	18
110	Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue. DNA Repair, 2019, 83, 102644.	1.3	18
111	DNA Damage, Repair, and Diseases. Journal of Biomedicine and Biotechnology, 2002, 2, 45-45.	3.0	17
112	Predicting and Preventing Hereditary Colorectal Cancer. JAMA - Journal of the American Medical Association, 2006, 296, 1521.	3.8	17
113	Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. DNA Repair, 2012, 11, 522-524.	1.3	17
114	Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients. Journal of Molecular Diagnostics, 2020, 22, 544-554.	1.2	17
115	Metastatic Lobular Breast Carcinoma Mimicking Primary Signet Ring Adenocarcinoma in a Patient With a Suspected CDH1 Mutation. Journal of Clinical Oncology, 2015, 33, e19-e21.	0.8	16
116	Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers. Oncotarget, 2017, 8, 26344-26355.	0.8	16
117	Is breast cancer a part of Lynch syndrome?. Breast Cancer Research, 2012, 14, 110.	2.2	15
118	Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing. JNCI Cancer Spectrum, 2020, 4, pkz095.	1.4	15
119	A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. Cancer Genetics and Cytogenetics, 2007, 179, 89-92.	1.0	14
120	Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. Breast Cancer Research and Treatment, 2012, 136, 931-933.	1.1	14
121	DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. Cancer Treatment Reviews, 2016, 44, 1-9.	3.4	14
122	BRCA1: Beyond double-strand break repair. DNA Repair, 2015, 32, 165-171.	1.3	13
123	A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male. Rare Tumors, 2011, 3, 141-145.	0.3	12
124	Identification of a Functional In Vivo p53 Response Element in the Coding Sequence of the Xeroderma Pigmentosum Group C Gene. Genes and Cancer, 2012, 3, 131-140.	0.6	12
125	IDH2 Mutation in a Patient with Metastatic Colon Cancer. New England Journal of Medicine, 2017, 376, 1991-1992.	13.9	12
126	Prevalence of Lynch syndrome in women with mismatch repairâ€deficient ovarian cancer. Cancer Medicine, 2021, 10, 1012-1017.	1.3	12

#	Article	IF	Citations
127	High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients. Clinical Cancer Research, 2019, 25, 5301-5314.	3.2	11
128	Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. Journal of Physical Education and Sports Management, 2018, 4, a003004.	0.5	10
129	Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations. Cancer Research, 2019, 79, CT138-CT138.	0.4	10
130	Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. Cancers, 2022, 14, 2716.	1.7	10
131	Identification of a novel p53 in-frame deletion in a Liâ€“Fraumeni-like family. Pediatric Blood and Cancer, 2008, 50, 914-916.	0.8	9
132	Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. Oncotarget, 2018, 9, 7832-7843.	0.8	9
133	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 2020, 4, 916-925.	1.5	9
134	Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precision Oncology, 2022, 6, e2100424.	1.5	9
135	Hereditary Gastric Cancer. JAMA Oncology, 2015, 1, 16.	3.4	8
136	Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer. Scientific Reports, 2020, 10, 5009.	1.6	8
137	Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?. JCO Precision Oncology, 2018, 2, 1-10.	1.5	7
138	DNA Damage Response Pathways and Cancer. , 2020, , 154-164.e4.		7
139	A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma. DNA Repair, 2021, 97, 103022.	1.3	7
140	Chromatin Remodeling in Response to BRCA2-Crisis. Cell Reports, 2019, 28, 2182-2193.e6.	2.9	6
141	Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford. JNCI Cancer Spectrum, 2020, 4, pkaa054.	1.4	6
142	Precision medicine to improve survival without increasing costs in advanced cancer patients.. Journal of Clinical Oncology, 2015, 33, e17641-e17641.	0.8	6
143	JAVELIN BRCA/ATM: A phase 2 trial of avelumab (antiâ€“PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.. Journal of Clinical Oncology, 2019, 37, TPS2660-TPS2660.	0.8	6
144	Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes. Cancers, 2022, 14, 728.	1.7	6

#	Article	IF	Citations
145	Family History As a Positive Prognostic Factor in Gastric Cancer. Journal of Clinical Oncology, 2012, 30, 683-684.	0.8	5
146	Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2â€“Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. JCO Precision Oncology, 2017, 1, 1-6.	1.5	5
147	Genomics in medicine: a novel elective rotation for internal medicine residents. Postgraduate Medical Journal, 2019, 95, 569-572.	0.9	5
148	Precision Oncology: A New Forum for an Emerging Field. JCO Precision Oncology, 2017, 1, 1-2.	1.5	4
149	A phase II clinical trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer.. Journal of Clinical Oncology, 2021, 39, TPS1109-TPS1109.	0.8	4
150	Enhancing Repair of Oxidative DNA Damage with Small-Molecule Activators of MTH1. ACS Chemical Biology, 2022, 17, 2074-2087.	1.6	4
151	A Young Woman With Bilateral Breast Cancer: Identifying a Genetic Cause and Implications for Management. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 512-517.	2.3	3
152	Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study. JCO Precision Oncology, 2018, 2, 1-12.	1.5	3
153	DNA Damage Response Pathways and Cancer. , 2008, , 139-152.		3
154	Abstract P5-04-03: Deconvoluting immune cell populations using â€˜in silico flow cytometryâ€™ with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC. , 2015, , .		3
155	Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer.. Journal of Clinical Oncology, 2015, 33, 1018-1018.	0.8	3
156	Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers.. Journal of Clinical Oncology, 2019, 37, 215-215.	0.8	3
157	Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Journal of Clinical and Translational Hepatology, 2020, 8, 1-8.	0.7	3
158	Somatic tumor testing implications for Lynch syndrome germline genetic testing. Cancer Genetics, 2022, 264-265, 16-22.	0.2	3
159	A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 115-115.	0.8	2
160	DNA Damage Response Pathways and Cancer. , 2014, , 142-153.e3.		2
161	Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.. Journal of Clinical Oncology, 2020, 38, 1549-1549.	0.8	2
162	Genetic Polymorphisms as Predictors of Breast Cancer Risk. Current Breast Cancer Reports, 2012, 4, 232-239.	0.5	1

#	Article	IF	Citations
163	Multiple-Gene Panels and the Future of Genetic Testing. Current Breast Cancer Reports, 2015, 7, 98-104.	0.5	1
164	BRCA1: a movement toward cancer prevention. Molecular and Cellular Oncology, 2015, 2, e979685.	0.3	1
165	Totally Unexpected: Nonsyndromic CDH1 Mutations and Hereditary Diffuse Gastric Cancer Syndrome. JCO Precision Oncology, 2017, 1, 1-2.	1.5	1
166	Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies. JCO Precision Oncology, 2018, 2, 1-4.	1.5	1
167	Statistical Methods in Precision Oncology. Journal of Clinical Oncology, 2020, 38, 660-661.	0.8	1
168	One Step Further Toward Defining the Exceptional Cancer Responder. Journal of the National Cancer Institute, 2021, 113, 3-4.	3.0	1
169	A quality outcomes analysis following treatment with personalized genomic cancer medicine.. Journal of Clinical Oncology, 2014, 32, 12-12.	0.8	1
170	Clinical impact of multi-gene panel testing for hereditary breast and ovarian cancer risk assessment.. Journal of Clinical Oncology, 2015, 33, 1513-1513.	0.8	1
171	Pathogenic germline mutations in emerging cancer genes: What happens after panel testing?. Journal of Clinical Oncology, 2017, 35, 1528-1528.	0.8	1
172	Preventive surgery after multiplex genetic panel testing (MGPT).. Journal of Clinical Oncology, 2019, 37, 1525-1525.	0.8	1
173	Implementation of a precision cancer program in an integrated health care system.. Journal of Clinical Oncology, 2015, 33, e17647-e17647.	0.8	1
174	Molecular profiling (MP) programs to increase access to targeted therapies in a rural setting.. Journal of Clinical Oncology, 2015, 33, e17576-e17576.	0.8	1
175	A Novel Framework for the Next Generation of Precision Oncology Targets. JAMA Oncology, 2022, 8, 974.	3.4	1
176	Comparative Analysis of Bio-Medical Imaging at 3.7 Terahertz with a High Power Quantum Cascade Laser. , 2006, , .		0
177	Identifying and Preventing High-risk Gastric Cancer Individuals With CDH1 Mutations. Annals of Surgery, 2008, 247, 715-716.	2.1	0
178	Lupus Antibody Tops Cancer Cells. Science Translational Medicine, 2012, 4, 157fs38.	5.8	0
179	Introducing the JCO Precision Oncology Molecular Tumor Board Case Discussion Series. JCO Precision Oncology, 2018, 2, 1-1.	1.5	0
180	Subtle endoscopic manifestations of diffuse signet cell gastric adenocarcinoma in patients with CDH1 mutations. Gastrointestinal Endoscopy, 2021, 94, 1146-1147.	0.5	0

#	Article	IF	Citations
181	Molecular Inversion Probes (MIPs) Identify Novel Areas of Allelic Imbalance in Childhood Leukemia.. Blood, 2007, 110, 1438-1438.	0.6	0
182	Seventh edition (2010) of gastric adenocarcinoma AJCC staging system: Is there room for improvement?. Journal of Clinical Oncology, 2012, 30, 77-77.	0.8	0
183	Abstract 1761: Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol-induced oxidative DNA damage. , 2012, , .		0
184	Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT.. Journal of Clinical Oncology, 2015, 33, 433-433.	0.8	0
185	Design and implementation of an informatics infrastructure for actionable precision oncology.. Journal of Clinical Oncology, 2015, 33, e17521-e17521.	0.8	0
186	Association of tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based therapy in breast cancer (BC) with therapy resistance.. Journal of Clinical Oncology, 2015, 33, 1094-1094.	0.8	0
187	Abstract PR07: Precision genomic medicine improves clinical outcomes in advanced cancer patients. , 2016, , .		0
188	Optimizing Genotype Matched Clinical Trial (GMCT) accrual in a community oncology program (COP).. Journal of Clinical Oncology, 2016, 34, e18036-e18036.	0.8	0
189	Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2016, 34, 1010-1010.	0.8	0
190	Yield of multiplex panel testing compared to expert opinion and validated prediction models.. Journal of Clinical Oncology, 2016, 34, 1509-1509.	0.8	0
191	Genomic profiling and targeted therapy in cholangiocarcinoma to yield positive clinical outcomes.. Journal of Clinical Oncology, 2016, 34, e23162-e23162.	0.8	0
192	Expanded yield of multiplex panel testing in fully accrued prospective trial.. Journal of Clinical Oncology, 2017, 35, 1525-1525.	0.8	0
193	Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort.. Journal of Clinical Oncology, 2017, 35, 1523-1523.	0.8	0
194	Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.. Journal of Clinical Oncology, 2017, 35, 1576-1576.	0.8	0
195	Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling.. Journal of Clinical Oncology, 2018, 36, 1582-1582.	0.8	0
196	Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling.. Journal of Clinical Oncology, 2018, 36, 1581-1581.	0.8	0
197	Abstract 4749: VISTA immune checkpoint deregulation in human triple-negative breast cancer. , 2018, , .		0
198	Gastric Cancer Registry: A comprehensive patient-reported resource for multidisciplinary and translational genomic approaches to gastric cancer.. Journal of Clinical Oncology, 2020, 38, 432-432.	0.8	0

#	Article	IF	Citations
199	The Gastric Cancer Registry: A Genomic Translational Resource for Multidisciplinary Research in Gastric Cancer. Cancer Epidemiology Biomarkers and Prevention, 0, , .	1.1	0
200	Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.. Journal of Clinical Oncology, 2022, 40, 525-525.	0.8	0